Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
FranceIPO:
17 October 2019Website:
http://www.innate-pharma.comNext earnings report:
12 September 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 05 Jul 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
IPHA Latest News
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced favorable results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides (MF). The results were presented at the ASCO 2024 Annual Meeting, in Chicago, Illinois. As of October 13, 2023, data cutoff, MF patients (n=107) received a median of 4 prior systemic therapies and had a median follow-up of 11.8 months. The data demonstrate that treatme.
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming investor conferences.
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced today that five abstracts with Innate's drug candidates have been accepted for the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, taking place May 31-June 4, 2024 in Chicago, Illinois. ASCO abstract details: Lacutamab Abstract: 7082 Abstract Title: Lacutamab in patients with relapsed and/or refractory mycosis fungoides: results from t.
Innate Pharma (IPHA) has received a Zacks Rank #2 (Buy), indicating increasing confidence in the company's potential earnings growth. This could lead to a rise in the stock price in the short run.
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma announces its participation in upcoming Investor Conference.
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its executive team are scheduled to participate in the upcoming investor conference, detailed below. Participants will be Sonia Quaratino, Executive Vice President, Chief Medical Officer, Yannis Morel, Executive Vice President, Chief Operating Officer and Arvind Sood, Executive Vice President, President of US Operations. 2nd Annual.
MARSEILLE, France--(BUSINESS WIRE)--Innate Pharma to present Nectin-4 Antibody Drug Conjugate IPH45 preclinical data at AACR 2024.
Innate Pharma (IPHA) stock moves up in the pre-market hours as the FDA lifts the partial clinical hold placed on a study evaluating lacutamab for Sezary syndrome.
Innate Pharma S.A. (NASDAQ:IPHA ) Q3 2023 Earnings Conference Call November 14, 2023 8:00 AM ET Company Participants Henry Wheeler - VP, IR and Communication Mondher Mahjoubi - CEO Sonia Quaratino - Chief Medical Officer Yannis Morel - EVP, BD and Product Portfolio Strategy Conference Call Participants Rabib Chaudhury - Leerink Partners Carly Kenselaar - Citi Arthur He - H.C.
MARSEILLE, France--(BUSINESS WIRE)-- #ANKET--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participate in upcoming investor conferences, detailed below. Jefferies London Healthcare Conference Event Date: November 15, 2023, London, UK 6th Annual Evercore ISI HealthCONx Conference Event Date: November 28, 2023, Miami, USA Investir Day Event Date: November 28, 2023, Paris, France About Innate Phar.
- 1(current)
What type of business is Innate Pharma SA?
Innate Pharma S.A., a biotechnology company, discovers, develops, and commercializes therapeutic antibodies for the treatment of oncology indications in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; Avdoralimab (IPH5401), a monoclonal antibody blocking C5a binding to C5aR1 that is in Phase II clinicals trials for the treatment of COVID-19, bullous pemphigoid, chronic spontaneous urticaria, and other inflammatory diseases; IPH5201, a blocking antibody that is in Phase 1 clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; and IPH6101, a NKp46-based NK cell engager for the generation and evaluation of up to two bispecific NK cell engagers. Its products in preclinical trials are IPH43, an anti-MICA/B antibody drug conjugate; Anti-Siglec-9, an antibody program; IPH65, a tetraspecific proprietary antibody; IPH25, a checkpoint inhibitor; and IPH62 and IPH64 programs. Innate Pharma S.A. has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. The company was incorporated in 1999 and is headquartered in Marseille, France.
What sector is Innate Pharma SA in?
Innate Pharma SA is in the Healthcare sector
What industry is Innate Pharma SA in?
Innate Pharma SA is in the Biotechnology industry
What country is Innate Pharma SA from?
Innate Pharma SA is headquartered in France
When did Innate Pharma SA go public?
Innate Pharma SA initial public offering (IPO) was on 17 October 2019
What is Innate Pharma SA website?
https://www.innate-pharma.com
Is Innate Pharma SA in the S&P 500?
No, Innate Pharma SA is not included in the S&P 500 index
Is Innate Pharma SA in the NASDAQ 100?
No, Innate Pharma SA is not included in the NASDAQ 100 index
Is Innate Pharma SA in the Dow Jones?
No, Innate Pharma SA is not included in the Dow Jones index
When does Innate Pharma SA report earnings?
The next expected earnings date for Innate Pharma SA is 12 September 2024